GlassScriptPhysician profile
Dwayne P Labatut
NPI 1760462782
$4,052.07
in general payments reported to CMS, 2019-2025
33 companies · $934 in 2025
The $934 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $913 · 2023: $836 · 2024: $733 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,132.28 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,102.98 | 2021-2025 | |
| Astellas Pharma US INC | $362.42 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $184.54 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $126.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $117.90 | 2022 | |
| Novo Nordisk INC | $113.77 | 2021-2025 | Saxenda, Wegovy |
| Jazz Pharmaceuticals INC. | $105.83 | 2021-2022 | |
| Lilly USA, LLC | $65.73 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $63.98 | 2022-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $48.77 | 2025 | Fanapt |
| Exact Sciences Corporation | $48.23 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $47.29 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $46.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.25 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $40.20 | 2021-2022 | |
| Antares Pharma, INC. | $39.60 | 2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $35.67 | 2021 | |
| Lundbeck LLC | $34.27 | 2024 | Vyepti |
| Phathom Pharmaceuticals, INC. | $34.05 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $32.57 | 2023-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $31.43 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.34 | 2022-2025 | Xifaxan |
| Vertex Pharmaceuticals Incorporated | $20.41 | 2025 | |
| Alfasigma USA, INC. | $18.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.65 | 2024 | Eliquis |
| Almatica Pharma LLC | $17.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2024 | Airsupra |
| Amarin Pharma, INC. | $15.46 | 2021 | |
| Abiomed | $14.98 | 2023 | Impella |
| Supernus Pharmaceuticals, INC. | $14.88 | 2023 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $14.78 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Labatut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.